Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Alexander Khoruts
Initial failure of FMT in breaking the cycle of recurrent C. difficile infections is associated with a greater risk of subsequent failure. Previous analysis showed that FMT failure is associated with delayed repair of fecal microbiota at one week after administration. The hypothesis underlying this trial is that increased symptom-free interval by administration of bezlotoxumab can improve the outcomes of a second FMT.
Age
18–100
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Informed consent.
2. Diagnosis of recurrent C. difficile infection based on symptoms and laboratory confirmation.
3. Failure of standard antibiotic therapies prior to the initial FMT
You may not be if
1. Pregnancy.
2. Class III or above heart failure.
Clareo Health | Rescue FMT with Bezlotoxumab for Recurrent C. Difficile Infection
